CLINICAL INSIGHT ON PATTERNS OF CARE AND PROGNOSTIC FACTORS IN ADULT HIGH GRADE GLIOMA: EXPERIENCE FROM A TERTIARY CANCER HOSPITAL FROM EASTERN INDIA
Keywords:Glioma, Brain Tumor, Radiotherapy, Indian data, Prognosis, survival, Glioblastoma
Objective: The Central Nervous System Tumors account for 2.4% of all malignancies in India, but are associated with high mortality in high-grade tumors which result in poor death-adjusted life years. This study focuses on patterns of care and prognostic factors of adult high-grade glioma to explore the unaddressed nuances in treating such patients.
Methods: It was a retrospective single institutional study from June 2018 to July 2021 with an age group between 16 to 70 years. All histopathologically or clinicoradiologically proven cases of high-grade (World Health Organization Grades III and IV) gliomas were assessed. Defaulters and recurrent glioma at presentation were excluded from the analysis. Baseline characteristics were analyzed by Chi-square and unpaired t-test, and the Kaplan– Meir test was used for survival analysis. p<0.05 was considered significant.
Results: 41 patients were accrued for final analysis with a median follow-up period of 18 months. The most common histology was Astrocytoma, followed by Glioblastoma with a female preponderance. The Frontal and Temporal lobe was the predominant site in the study population. A majority (82%) of the patients underwent maximal safe resection followed by chemoradiation therapy (63.4%). Median progression free survival was 24 months and 8 months for Grades III and IV gliomas, respectively. The median overall survival for Grade IV gliomas was 7 months.
Conclusion: Resection status, Grade IV, IDH and 1p19q codeletion status were significant prognostic factors, while intensity modulated radiotherapy showed better dosimetry. More prospective randomized studies with larger sample sizes and longer follow-ups are required for validation and drafting an outcome nomogram.
Sharma A, Graber JJ. Overview of prognostic factors in adult gliomas. Ann Palliat Med 2021;10:863-74. doi: 10.21037/apm-20-640. Epub 2020 Aug 7. PMID: 32787379
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World health organization classification of tumors of the central nervous system: A summary. Acta Neuropathol 2016;131:803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9. PMID: 27157931.
Globocan India. Population Fact Sheets; 2020. p. 1-2. Available from: https://gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf
Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, et al. CBTRUS Statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol 2017;19:v1-88. doi: 10.1093/neuonc/nox158. PMID: 29117289; PMCID: PMC5693142.
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66. doi: 10.1016/S1470-2045(09)70025-7. Epub 2009 Mar 9. PMID: 19269895
Chang EL, Akyurek S, Avalos T, Rebueno N, Spicer C, Garcia J, et al. Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. Int J Radiat Oncol Biol Phys 2007;68:144-50. doi: 10.1016/j.ijrobp.2006.12.009. Epub 2007 Feb 15. PMID: 17306935.
Zhao F, Li M, Kong L, Zhang G, Yu J. Delineation of radiation therapy target volumes for patients with postoperative glioblastoma: A review. Onco Targets Ther 2016;9:3197-204. doi: 10.2147/OTT.S104241. PMID: 27313465; PMCID: PMC4892826.
Colevas AD, Setser A. The NCI common terminology criteria for adverse events (CTCAE) v 3.0 is the new standard for oncology clinical trials. J Clin Oncol 2004;22:6098.
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of tumors of the central nervous system: A summary. Neuro Oncol 2021;23:1231-51. doi: 10.1093/neuonc/ noab106. PMID: 34185076; PMCID: PMC8328013
Mahajan S, Suri V, Sahu S, Sharma MC, Sarkar C. World health organization classification of tumors of the central nervous system 5th edition (WHO CNS5): What’s new? Indian J Pathol Microbiol 2022;65:S5-13.
Dasgupta A, Gupta T, Jalali R. Indian data on central nervous tumors: A summary of published work. South Asian J Cancer 2016;5:147-53. doi: 10.4103/2278-330X.187589. PMID: 27606302; PMCID: PMC4991137
Shastry AH, Thota B, Srividya MR, Arivazhagan A, Santosh V. nuclear protein phosphatase 1 α (PP1A) Expression is associated with poor prognosis in p53 expressing glioblastomas. Pathol Oncol Res 2016;22:287-92. doi: 10.1007/s12253-015-9928-5. Epub 2015 Aug 9. PMID: 26253838
Srinivasan S, Patric IR, Somasundaram K. A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One 2011;6:e17438. doi: 10.1371/journal.pone.0017438. PMID: 21483847; PMCID: PMC3069027
Jha P, Suri V, Singh G, Jha P, Purkait S, Pathak P, et al. Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults. Diagn Mol Pathol 2011;20:225-32. doi: 10.1097/PDM.0b013e31821c30bc. PMID: 22089350
Goda JS, Dutta D, Raut N, Juvekar SL, Purandare N, Rangarajan V, et al. Can multiparametric MRI and FDG-PET predict outcome in diffuse brainstem glioma? A report from a prospective phase-II study. Pediatr Neurosurg 2013;49:274-81. doi: 10.1159/000366167. Epub 2014 Sep 25. PMID: 25277867
Shukla B, Agarwal S, Suri V, Pathak P, Sharma MC, Gupta D, et al. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors. Neurol India 2009;57:559-66. doi: 10.4103/0028- 3886.57795. PMID: 19934553
Suri V, Jha P, Agarwal S, Pathak P, Sharma MC, Sharma V, et al. Molecular profile of oligodendrogliomas in young patients. Neuro Oncol 2011;13:1099-106. doi: 10.1093/neuonc/nor146. PMID: 21937591; PMCID: PMC3177666
Ghose A, Lim G, Husain S. Treatment for glioblastoma multiforme Current guidelines and Canadian practice. Curr Oncol 2010;17:52-8. doi: 10.3747/co.v17i6.574. PMID: 21151410; PMCID: PMC2993441
Kumar N, Kumar R, Sharma SC, Mukherjee A, Khandelwal N, Tripathi M, et al. Impact of volume of irradiation on survival and quality of life in glioblastoma: A prospective, phase 2, randomized comparison of RTOG and MDACC protocols. Neurooncol Pract 2020;7:86-93. doi: 10.1093/ nop/npz024. Epub 2019 Jul 18. PMID: 32257287; PMCID: PMC7104885
Van den Bent MJ, Tesileanu CM, Wick W, Sanson M, Brandes AA, Clement PM, et al. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): Second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol 2021;22:813-23. doi: 10.1016/ S1470-2045(21)00090-5. Epub 2021 May 14. PMID: 34000245; PMCID: PMC8191233
Mizumoto M, Yamamoto T, Takano S, Ishikawa E, Matsumura A, Ishikawa H, et al. Long-term survival after treatment of glioblastoma multiforme with hyperfractionated concomitant boost proton beam therapy. Pract Radiat Oncol 2015;5:e9-16. doi: 10.1016/j. prro.2014.03.012. Epub 2014 May 19. PMID: 25413424
How to Cite
Copyright (c) 2022 Dr. Annesha Sen, Dr. Amitabha Manna, Dr. Bidyut Mandal , Dr. Abhishek Basu
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.